Loading...
Loading...
Coronado Biosciences,
Inc.
CNDO, a biopharmaceutical company focused on the development of
novel immunotherapy biologic agents for the treatment of autoimmune diseases
and cancer, announced today that it closed its previously announced
underwritten public offering of 5,750,000 shares of its common stock at a
price to the public of $5.00 per share for gross proceeds to Coronado of $28.8
million. The shares include 750,000 shares of common stock sold pursuant to
the over-allotment option granted by Coronado to the underwriters, which
option was exercised in full. Coronado expects net proceeds of the offering
will be approximately $26.5 million, after deducting underwriting commissions
and other offering expenses.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in